Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune DisordersRead More
Unleashing the power of novel protein therapeutics to transform the care of and prospects for millions of patients who suffer from life-threatening diseases depends heavily on continued advances in technologies and methods for protein expression. This is particularly critical for medicines that are based on recombinant proteins, such as monoclonal antibodies and difficult-to-express proteins, including Fc-fusion proteins, bi-specific monoclonal antibodies, and novel scaffolds. Selexis is a scientific pioneer and global leader in mammalian (suspension-adapted CHO-K1) cell line development that has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for two decades. Selexis’s proprietary SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.